187 related articles for article (PubMed ID: 8857072)
21. Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors.
Bieck PR; Antonin KH
J Neural Transm Suppl; 1989; 28():21-31. PubMed ID: 2794993
[TBL] [Abstract][Full Text] [Related]
22. Influence of food on the tyramine pressor effect during chronic moclobemide treatment of healthy volunteers.
Audebert C; Blin O; Monjanel-Mouterde S; Auquier P; Pedarriosse AM; Dingemanse J; Durand A; Cano JP
Eur J Clin Pharmacol; 1992; 43(5):507-12. PubMed ID: 1483487
[TBL] [Abstract][Full Text] [Related]
23. Interaction of moclobemide and tricyclic antidepressants with the tyramine pressor effect in rats.
Burkard W; d'Agostini F; Kettler R; Da Prada M
Psychopharmacology (Berl); 1992; 106 Suppl():S35-6. PubMed ID: 1546137
[TBL] [Abstract][Full Text] [Related]
24. Blood pressure response to tyramine-enriched meal before and during MAO-inhibition in man: influence of dosage regimen.
Müller T; Gieschke R; Ziegler WH
J Neural Transm Suppl; 1988; 26():105-14. PubMed ID: 3162949
[TBL] [Abstract][Full Text] [Related]
25. Linezolid, a novel oxazolidinone antibiotic: assessment of monoamine oxidase inhibition using pressor response to oral tyramine.
Antal EJ; Hendershot PE; Batts DH; Sheu WP; Hopkins NK; Donaldson KM
J Clin Pharmacol; 2001 May; 41(5):552-62. PubMed ID: 11361052
[TBL] [Abstract][Full Text] [Related]
26. The advent of selective monoamine oxidase A inhibitor antidepressants devoid of the cheese reaction.
Youdim MB
Acta Psychiatr Scand Suppl; 1995; 386():5-7. PubMed ID: 7717095
[No Abstract] [Full Text] [Related]
27. Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo.
Versiani M; Nardi AE; Figueira IL; Stabl M
Acta Psychiatr Scand Suppl; 1990; 360():24-8. PubMed ID: 2123366
[TBL] [Abstract][Full Text] [Related]
28. Hypotensive action and weak potentiation of tyramine effect by moclobemide in rats.
Da Prada M; Burkard WP
Acta Psychiatr Scand Suppl; 1990; 360():106-7. PubMed ID: 2248060
[TBL] [Abstract][Full Text] [Related]
29. Interaction between orally administered tyramine and moclobemide.
Zimmer R; Puech AJ; Philipp F; Korn A
Acta Psychiatr Scand Suppl; 1990; 360():78-80. PubMed ID: 2248083
[TBL] [Abstract][Full Text] [Related]
30. Effects of a tyramine-enriched meal on blood pressure response in healthy male volunteers treated with selegiline transdermal system 6 mg/24 hour.
Blob LF; Sharoky M; Campbell BJ; Kemper EM; Gilmor MG; VanDenberg CM; Azzaro AJ
CNS Spectr; 2007 Jan; 12(1):25-34. PubMed ID: 17192761
[TBL] [Abstract][Full Text] [Related]
31. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide.
Da Prada M; Zürcher G; Wüthrich I; Haefely WE
J Neural Transm Suppl; 1988; 26():31-56. PubMed ID: 3283290
[TBL] [Abstract][Full Text] [Related]
32. Combined and selective monoamine oxidase inhibition in the treatment of depression in Parkinson's disease.
Jansen Steur EN; Ballering LA
Adv Neurol; 1999; 80():505-8. PubMed ID: 10410764
[No Abstract] [Full Text] [Related]
33. Studies of selective and reversible monoamine oxidase inhibitors.
Mann JJ; Aarons SF; Frances AJ; Brown RD
J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):62-6. PubMed ID: 6429130
[TBL] [Abstract][Full Text] [Related]
34. An Australian multicentre study of moclobemide versus amitriptyline in the treatment of depression.
Evans L; George T; O'Sullivan B; Mitchell P; Johnson G; Adena M
Aust N Z J Psychiatry; 1992 Sep; 26(3):454-8. PubMed ID: 1417632
[TBL] [Abstract][Full Text] [Related]
35. Effect of oral linezolid on the pressor response to intravenous tyramine.
Cantarini MV; Painter CJ; Gilmore EM; Bolger C; Watkins CL; Hughes AM
Br J Clin Pharmacol; 2004 Nov; 58(5):470-5. PubMed ID: 15521893
[TBL] [Abstract][Full Text] [Related]
36. MAO inhibitors: risks, benefits, and lore.
Wimbiscus M; Kostenko O; Malone D
Cleve Clin J Med; 2010 Dec; 77(12):859-82. PubMed ID: 21147941
[TBL] [Abstract][Full Text] [Related]
37. A risk-benefit assessment of moclobemide in the treatment of depressive disorders.
Norman TR; Burrows GD
Drug Saf; 1995 Jan; 12(1):46-54. PubMed ID: 7741983
[TBL] [Abstract][Full Text] [Related]
38. Bovril and moclobemide: a novel therapeutic strategy for central autonomic failure.
Karet FE; Dickerson JE; Brown J; Brown MJ
Lancet; 1994 Nov; 344(8932):1263-5. PubMed ID: 7967987
[TBL] [Abstract][Full Text] [Related]
39. Cardiovascular sympathomimetic amine interactions in rats treated with monoamine oxidase inhibitors and the novel oxazolidinone antibiotic linezolid.
Humphrey SJ; Curry JT; Turman CN; Stryd RP
J Cardiovasc Pharmacol; 2001 May; 37(5):548-63. PubMed ID: 11336106
[TBL] [Abstract][Full Text] [Related]
40. Modification of the cardiovascular effects of ephedrine by the reversible monoamine oxidase A-inhibitor moclobemide.
Dingemanse J; Guentert T; Gieschke R; Stabl M
J Cardiovasc Pharmacol; 1996 Dec; 28(6):856-61. PubMed ID: 8961085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
